DavidCharlesFajgenbaumMDMBA, MSc

PubMed

• 223 citations
  International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease
  Frits van Rhee, Peter M. Voorhees, Angela Dispenzieri, Alexander Fosså, Gordan Srkalovic
  Blood. 2018-11-15
• 36 citations
  Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease.
  David C. Fajgenbaum
  Hematology. American Society of Hematology. Education Program. 2018-11-30
• 35 citations
  Predictors of response to anti-IL6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease: secondary analyses of phase II clinical trial...
  Deanna E Morra, Sheila K Pierson, Dustin Shilling, Sepideh Nemat, Carlos Appiani
  British Journal of Haematology. 2019-01-01

Journal Articles

• Cytokine Storm  
  David Fajgenbaum, MD, The New England Journal of Medicine
• Predictors of Response to Anti‐IL6 Monoclonal Antibody Therapy (Siltuximab) in Idiopathic Multicentric Castleman Disease: Secondary Analyses of Phase II Clinical Trial...  
  David C Fajgenbaum, Craig Tendler, British Journal of Haematology
• International, Evidence-Based Consensus Treatment Guidelines for Idiopathic Multicentric Castleman Disease  
  Aaron Goodman, Corey Casper, Sudipto Mukherjee, Peter Voorhees, Angela Dispenzieri, David C Fajgenbaum, Amy Chadburn, Razelle Kurzrock, Raj Jayanthan, Sunita Nasta, Th..., Blood
• A novel FAS mutation with variable expressivity in a family with unicentric and idiopathic multicentric Castleman disease  
  Turner S. Baker, Kristyne J. Gambino, Lawrence Schriefer, Jung-Yeon Lim, Karyn Meltz Steinberg, David C. Fajgenbaum, Alejandro Mart�n Garc�a-Sancho, Minji Byun, Blood Advances, 1/1/2018
• Perspective From the 5th International Pemphigus and Pemphigoid Foundation Scientific Conference  
  Jinmin Lee, Victoria P. Werth, Russell P. Hall, R�diger Eming, Janet A. Fairley, David C. Fajgenbaum, Karen E. Harman, Marcel F. Jonkman, Neil J. Korman, Ralf J. Ludwi..., Front Med, 1/1/2018
• Effectiveness of rituximab-containing treatment regimens in idiopathic multicentric Castleman disease  
  Yujun Dong, Lu Zhang, Lin Nong, Lihong Wang, Zeyin Liang, Daobin Zhou, David C. Fajgenbaum, Hanyun Ren, Jian Li, Annals of Hematology, 1/1/2018
• Schnitzler syndrome co-occurring with idiopathic multicentric Castleman disease that responds to anti-IL-1 therapy: a case report and clue to pathophysiology  
  Simon Soudet, David C Fajgenbaum, L. Scherman, C. Delattre, A . Forestier, A. Lanteri, E. Hachulla, PY Hatron, David Launay, Louis Terriou, Current Research in Translational Medicine, 1/1/2018
• Plasma proteomics identifies a 'chemokine storm' in idiopathic multicentric Castleman disease  
  Sheila K. Pierson, Aaron J. Stonestrom, Dustin Shilling, Jason Ruth, Christopher S. Nabel, Amrit Singh, Yue Ren, Katie Stone, Hongzhe Li, Frits van Rhee, David C. Fajg..., American Journal of Hematology, 1/1/2018
• The full spectrum of Castleman Disease: 273 patients studied over 20 years  
  Eric Oksenhendler, David Boutboul, David C. Fajgenbaum, Adrien Mirouse, Claire Fieschi, Marion Malphettes, Laetitia Vercellino, V�ronique Meignin, Laurence G�rard, Lio..., British Journal of Hematology, 1/1/2018
• Predictors of response to anti-IL6 monoclonal antibody therapy(siltuximab) in idiopathic multicentric Castleman disease:secondary analyses of phase II clinical trial data  
  Deanna E. Morra, Sheila K. Pierson, Dustin Shilling, Sepideh Nemat, Carlos Appiani, Mary Guilfoyle, Craig Tendler, Frits van Rhee, David C. Fajgenbaum, British Journal of Haematology, 1/1/2018
• Potential value of FDG PET-CT in diagnosis and follow-up of TAFRO syndrome  
  Fatemah Behnia, Saeed Elojeimy, Manuela Matesan, David C. Fajgenbaum, Annals of Hematology, 1/1/2017
• TAFRO Syndrome in Caucasians: A Case Report and Review of the Literature  
  Celine Louis, Sandrine Vijgen, Kaveh Samii, Yves Chalandon, Louis Terriou, David Launay, David C. Fajgenbaum, Jorg D. Seebach, Yannick D. Muller, Frontiers in Medicine, 1/1/2017
• Leveraging information and collaboration to cure disease  
  David C. Fajgenbaum, Information Services & Use, 1/1/2017
• TAFRO syndrome: New subtype of idiopathic multicentric Castleman disease  
  Gordan Srkalovic, Inga Marijanovic, Maya B Srkalovic, David C. Fajgenbaum, Bosn J Basic Med Sci, 1/1/2017
• The future of Castleman disease research: proceedings from 2015 and 2016 annual meetings  
  Michael P. Croglio, Raj K. Jayanthan, Hayley Williamson, Melanie Kier, Amy Y. Liu, Helen L. Partridge, Sheila K. Pierson, Jason R. Ruth, David C. Fajgenbaum, Journal of Rare Disorders, 1/1/2017
• Idiopathic Multicentric Castleman's Disease: A Systematic Literature Review  
  Amy Y. Liu, Christopher S. Nabel, Brian S. Finkelman, Jason R. Ruth, Razelle Kurzrock, Frits van Rhee, Vera P. Krymskaya, Dermot P. Kelleher, Arthur H. Rubenstein, Dav..., The Lancet Haematology, 1/1/2016
• Rare Disease Research Requires (and benefits from) Global Collaboration: Three Examples from the Castleman Disease Collaborative Network  
  Hayley Williamson, Grant Mitchell, Emily Zhen, Auryn Enciso, Samantha Kass Newman, Deise Ahagon, Mike Croglio, Jason Ruth, Raj Jayanthan, Amy Yutong Liu, Alexander Sua..., Revista de Medicina, 1/1/2016
• The Collaborative Network Approach: A New Framework to Accelerate Castleman Disease and Other Rare Disease Research  
  David C. Fajgenbaum, Jason R. Ruth, Dermot P. Kelleher, Arthur H. Rubenstein, The Lancet Haematology, 1/1/2016
• Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease  
  Noriko Iwaki, David C. Fajgenbaum, Christopher S. Nabel, Yuka Gion, Eisei Kondo, Mitsuhiro Kawano, Taro Masunari, Isao Yoshida, Hiroshi Moro, Koji Nikkuni, Kazue Takai..., American Journal of Hematology, 1/1/2016
• A Rare Disease That Picked the Wrong Family: Fighting Back to Help a Loved One and as a Tool for Actively Coping A review of Rare, a documentary video produced directe...  
  David C. Fajgenbaum, Death Studies, 1/1/2015
• Living Life Laser-Focused: A Young Man Forced To Be Both Doctor and Patient  
  Alessia Minicozzi & David C. Fajgenbaum, Journal of Clinical Research & Bioethics, 1/1/2015
• Eruptive Cherry Hemangiomatosis associated with Multicentric Castleman's Disease: A Case Report and possible Mechanism  
  David C. Fajgenbaum, Frits van Rhee, Adnan Nasir, Misha Rosenbach, Jason Reutter, JAMA Dermatology, 1/1/2013
• Building a Network of Grief Support on College Campuses: A National Grassroots Initiative  
  David C. Fajgenbaum, Ben Chesson, Robin Lanzi, The Journal of College Student Psychotherapy, 1/1/2012
• Join now to see all

Books/Book Chapters

• Hematology/Oncology Clinics of North America: Castleman's Disease 
  Chapter: Castleman Disease Pathogenesis 
  David C. Fajgenbaum & Dustin ShillingEditors: Frits van Rhee, Nikhil C. Munshi.Elsevier2018
• Multiple myeloma, the state of the art 
  Chapter: Castleman Disease 
  Page 259 - 270Amy Y Liu & David C. FajgenbaumEditors: Jorge Vega.Permanyer2017
• We Get It: Voices of Grieving College Students and Young Adults 
  Heather Servaty-Seib & David C. FajgenbaumJessica Kingsley Publishers2015
• Georgetown Leadership Book 
  Chapter: Turning ideas into enterprises: Young social entrepreneurship on the Hilltop and beyond 
  David C. Fajgenbaum2007
• Join now to see all

Abstracts/Posters

• Type I Interferon Response Identified through Phenotypic and Transcriptional Profiling of Circulating Immune Cells during Idiopathic Multicentric Castleman Disease Flare
  David C Fajgenbaum, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Quantitative Changes in Serum Proteins Including CXCL13 Are Early Indicators of Response to Anti-IL6 Therapy in Idiopathic Multicentric Castleman Disease
  David C Fajgenbaum, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Hypercytokine-Producing Cells and Oligoclonal T-Cell Populations in Lymph Nodes from Castleman Disease Patients
  Anna Wiing, Wenzhao Meng, Gerald Wertheim, Dale Frank, Michele Paessler, Megan S. Lim, Eline T. Luning Prak, David C Fajgenbaum, Vinodh Pillai, Blood (ASH Annual Meeting Abstracts), 1/1/2018
• Pi3k/Akt/Mtor Pathway Activity Is Increased in Lymph Node Tissue from Idiopathic Multicentric Castleman Disease Patients with Tafro Syndrome
  Dustin Shilling, Dale M Kobrin, David C Fajgenbaum, Blood (ASH Annual Meeting Abstracts), 1/1/2018
• Oligoclonal Expansion of Cd8+ T Cells during Idiopathic Multicentric Castleman Disease Flares Suggests an Antigen Driven Process
  Dustin Shilling, Jason E Stadanlick, Wenzhao Meng, Abhishek Rao, Vera P Krymskaya, Eline T. Luning Prak, Evgeniy B Eruslanov, David C Fajgenbaum, Blood (ASH Annual Meeting Abstracts), 1/1/2018
• Serum Proteomics Reveals Distinct Subtypes Associated with Treatment Response in Idiopathic Multicentric Castleman Disease
  Dustin Shilling, Jason R Ruth, Christopher Sheild Nabel, Sheila K Pierson, Mary Guilfoyle, Craig Tendler, Manjula P Reddy, Michael Weinblatt, Nancy Shadick, Mark Bower..., Blood (ASH Annual Meeting Abstracts), 1/1/2018
• Single-Cell RNA-Sequencing of Peripheral Blood Mononuclear Cells Reveals Changes in Immune Cell Composition and Distinct Inflammatory Gene Expression Profiles during I...
  Ruth-Anne Langan, Dustin Shilling, Michael Gonzalez, Charlly Kao, HakonHakonarson, Taku Kambayashi, David C Fajgenbaum, Blood (ASH Annual Meeting Abstracts), 1/1/2018
• Virome Capture Sequencing in Castleman disease identifies associations with herpesviridae family members but no novel viruses
  Christopher S. Nabel, Stephen Sameroff, Dustin Shilling, Jason Ruth, Mitsuhiro Kawano, Yasuharu Sato, Noriko Iwaki, Federico Valdivieso, Michael Feldman, Katie Stone, ..., Blood (ASH Annual Meeting Abstracts), 1/1/2017
• Prolonged Remission Achieved in a Relapsing Idiopathic Multicentric Castleman Disease Patient with a Novel, Targeted Treatment Approach
  David C. Fajgenbaum, Dustin Shilling, Helen L. Partridge,Sheila Pierson, Jason R. Ruth, Christopher S. Nabel, Vandana Chaturvedi, Michael B. Jordan, MD5, Adam D. Cohen..., Blood (ASH Annual Meeting Abstracts), 1/1/2017
• Preliminary Results from Accelerate, an International, Web-Based, Natural History Registry of Castleman Disease
  David C. Fajgenbaum, Sheila K. Pierson, Dustin Shilling, Cooper Gardner, Amy Y. Liu, Jasira Ziglar, Shawnee Bernstein, Sarah Mann, Jeremy Zuckerberg, Martin Lukac, Raj..., Blood (ASH Annual Meeting Abstracts), 1/1/2017
• Quantification of Plasma Proteins from Idiopathic Multicentric Castleman Disease Flares and Remissions Reveals 'Chemokine Storm' and Separates Clinical Subtypes
  Sheila Pierson, Aaron James Stonestrom, Jason R Ruth, Dustin Shilling, Hongzhe Li, Yue Ren, Katie Stone, Frits van Rhee, David C. Fajgenbaum, Blood (ASH Annual Meeting Abstracts), 1/1/2017
• Join now to see all

Lectures

• Frontiers in Medicine: Personalized Medicine 
  1/1/2019
• MOD1 Genetics Case Presentations 
  1/1/2019
• Overtime: Battling a deadly disease as a physician, researcher, patient, and entrepreneur 
  1/1/2019
• Anxiety-Provoking Consults: Macrophage Activation Syndrome, Castleman Disease, and Hypereosinophilia 
  60th American Society of Hematology Annual Meeting - 12/1/2018
• Fighting for My Life: Orphan Diseases and the Quest for Cures 
  Austin, TX - 1/1/2018
• Personalized, Personalized Medicine for Rare Diseases 
  New York, NY - 1/1/2018
• ACCELERATE: Towards Personalized Medicine for Castleman Disease 
  Hopital St. Louis, Paris, France - 1/1/2018
• Personalized, personalized medicine in idiopathic multicentric Castleman disease 
  Dana Farber Cancer Institute, Boston, MA - 1/1/2018
• The Collaborative Network Approach: Accelerating research and treatment discovery through international collaboration and patient engagement 
  Orlando, FL - 1/1/2018
• The Collaborative Network Approach: Accelerating research and treatment discovery for Castleman disease through international collaboration and patient engagement 
  Dana Farber Cancer Institute, Boston, MA - 1/1/2018
• Accelerating research and therapy for Castleman disease 
  Palo Alto, CA - 1/1/2018
• A "Personalized Approach" to Treating Castleman disease 
  Milan, Italy - 1/1/2018
• Personalized, Personalized Medicine: Advancing Science and Survivorship for Castleman Disease 
  Tarrytown, NY - 1/1/2018
• Personalized, Personalized Medicine 
  Multiple locations, 2017, 2018 - 1/1/2018
• Personalized, Personalized Medicine: Research, Collaboration, and Remission 
  University of Pennsylvania, Philadelphia, PA - 1/1/2018
• Using an old transplant drug to hit novel targets in the cytokine storm disorder, idiopathic multicentric Castleman disease 
  University of Pennsylvania, Philadelphia, PA - 1/1/2018
• Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease 
  San Diego, CA - 1/1/2018
• Personalized, Personalized Medicine: Using 'omics' Research and Team Science to Advance Understanding of idiopathic multicentric Castleman disease 
  1/1/2017
• What Should Patients Expect when Funding Basic Research for Rare Diseases: A Patient Advocate's Story 
  1/1/2017
• Overtime 
  Las Vegas, NV, 2017; Boston, MA, 2017 - 1/1/2017
• Targeted treatment for HHV-8-negative, idiopathic multicentric Castleman disease 
  Silver Spring, MD - 1/1/2017
• Personalized, Personalized Medicine: Using 'omics' and Team Science to Advance Understanding of Idiopathic multicentric Castleman disease 
  Grand Rounds, Philadelphia, PA - 1/1/2017
• Overtime: Fighting to cure diseases when every second counts 
  Charlotte, NC - 1/1/2017
• Personalized, Personalized Medicine: Leveraging 'omic' data and team science to uncover a novel therapeutic target for iMCD 
  1/1/2017
• Treating my own disease 
  New York, NY - 1/1/2017
• Join now to see all

Other

• Unicentric Castleman disease 
  David C. Fajgenbaum, UpToDate
  1/1/2018
• HHV-8-associated multicentric Castleman disease 
  David C. Fajgenbaum, UpToDate
  1/1/2018
• HHV-8-negative/idiopathic multicentric Castleman disease 
  David C. Fajgenbaum, UpToDate
  1/1/2018
• Chip Chambers: For rare disease patients a pathway to hundreds of new therapies 
  Max Bronstein, Emil Kakkis, David C. Fajgenbaum, Health Affairs Blog
  1/1/2017
• Castleman Disease 
  David C. Fajgenbaum, NORD
  https://rarediseases.org/rare-diseases/castlemans-disease/
  1/1/2017
• Ask the Hematologists: What are your treatment approaches to Castleman disease with the advent of anti-interleukin-6 therapy? 
  Frits van Rhee & David C. Fajgenbaum, The Hematologist: ASH News and Reports
  1/1/2015
• Death and Loss in the Future as it Relates to Young Adults and National Students of AMF 
  David C. Fajgenbaum & Lisa Fajgenbaum, The ADEC Forum
  1/1/2013
• National Students of AMF: Peer Support and Service as Therapeutic Supports Among Grieving College Students 
  David C. Fajgenbaum, The ADEC Forum
  1/1/2012
• Join now to see all